- "The impressive local response rate seen in these two studies was determined by lesion measurements and digital imaging data," says Dr. Hope Rugo. "Patients are pleased with the local control in the treated areas. I look forward to continuing my involvement in the Phase 2 portion of the DIGNITY study and its future application to clinical development of ThermoDox across different cancers."
- Press release
- CLSN +8.4% premarket
at MarketWatch.com (Mar 8, 2013)